IgA肾病患者肾衰竭后的结局:与糖尿病肾病及其他肾小球疾病比较
该纵向队列研究纳入澳大利亚1965-2023年因IgA肾病、糖尿病肾病或其他肾小球疾病开始维持透析的44,659例肾衰竭患者,中位随访53个月。IgA肾病患者全因和心血管死亡风险低于其他肾小球疾病,进入移植等待名单率更高;糖尿病肾病患者全因和心血管死亡风险高于IgA肾病,但癌症死亡风险较低,进入移植等待名单率更低。
要点
- IgA肾病肾衰竭患者全因死亡风险低于其他肾小球疾病(HR 0.69)。
- IgA肾病患者进入移植等待名单率高于其他肾小球疾病(HR 1.55)。
- 糖尿病肾病患者全因死亡风险高于IgA肾病(HR 1.58),移植等待名单率更低(HR 0.64)。
核心结论
- 不同病因肾衰竭患者的生存和进入移植等待名单存在差异。
- IgA肾病患者生存期长于糖尿病肾病或其他肾小球疾病患者,且更常进入移植等待名单。
研究设计与样本
- 纵向队列研究,纳入澳大利亚1965-2023年开始维持透析的肾衰竭患者44,659例,其中IgA肾病4,925例,其他肾小球疾病15,079例,糖尿病肾病24,655例;中位随访53个月(IQR 23.3-109.8)。
主要发现
- IgA肾病年龄标化发病率近二十年保持稳定(EAPC -0.01%,95% CI -0.80至0.78)。
- 与其他肾小球疾病相比,IgA肾病患者全因死亡风险较低(HR 0.69,95% CI 0.65-0.73;p<0.001),心血管死亡风险较低(HR 0.67,95% CI 0.60-0.74;p<0.001),进入移植等待名单率较高(HR 1.55,95% CI 1.39-1.73;p<0.001)。
- 与IgA肾病相比,糖尿病肾病患者全因死亡风险较高(HR 1.58,95% CI 1.53-1.64;p<0.001),心血管死亡风险较高(HR 1.81,95% CI 1.71-1.91;p<0.001),癌症死亡风险较低(HR 0.82,95% CI 0.70-0.95;p=0.009),进入移植等待名单率较低(HR 0.64,95% CI 0.60-0.69;p<0.001)。
临床怎么用
- 对于IgA肾病所致肾衰竭患者,应积极评估肾移植候选资格并推动进入等待名单。
- 糖尿病肾病所致肾衰竭患者死亡风险较高,需加强心血管风险管理。
局限性
- 存在残余混杂。
- 活检实践差异可能导致诊断分类错误。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: IgA nephropathy (IgAN) is a major cause of kidney disease worldwide, yet contemporary comparative outcome data following kidney failure are limited. We compared trends in access to kidney transplantation and mortality among patients with kidney failure due to IgAN, to those with diabetic kidney disease (DKD) or other glomerular diseases (GD). STUDY DESIGN: Longitudinal cohort study. SETTING & PARTICIPANTS: Patients with kidney failure initiating maintenance dialysis (1965-2023) due to IgAN, DKD, or other GD in Australia. EXPOSURE: Kidney failure etiology. OUTCOMES: All-cause death, death from cardiovascular disease and cancer, and entry onto the deceased donor kidney transplant waitlist. ANALYTICAL APPROACH: Age-standardized incidence, prevalence, and mortality rates and temporal trends assessed using log-linear regression-derived estimated annual percentage change (EAPC). Associations between kidney failure etiology and outcomes estimated using inverse probability treatment-weight (IPTW)- adjusted Cox proportional hazards models. RESULTS: 44,659 patients (4,925 with IgAN; 15,079 with other GD; 24,655 with DKD) were studied with a median follow-up of 53 months (IQR 23.3-109.8). The age-standardized incidence of IgAN remained stable over the past two decades (EAPC -0.01%, 95% CI - 0.80 to 0.78). Compared with other GD, patients with IgAN experienced lower all-cause (HR 0.69, 95% CI 0.65-0.73; p < 0.001) and cardiovascular (HR 0.67, 95% CI 0.60-0.74; p < 0.001) mortality, and increased rates of being placed on the transplant waitlist (HR 1.55, 95% CI 1.39-1.73; p < 0.001). Compared with IgAN, patients with DKD had higher all-cause (HR 1.58, 95% CI 1.53-1.64, p<0.001) and cardiovascular mortality (HR 1.81, 95% CI 1.71-1.91, p<0.001), lower cancer-related mortality (HR 0.82, 95% CI 0.70-0.95, p=0.009), and lower rates of being placed on the transplant waitlist (HR 0.64, 95% CI 0.60-0.69, p<0.001). LIMITATIONS: Residual confounding, diagnostic misclassification due to variation in biopsy practices. CONCLUSION: Differences in survival and placement onto the kidney transplant waitlist exist across patients with different etiologies of kidney failure. Individuals with IgAN have longer survival and enter the transplant waitlist more often than those with DKD or other GD.
引用
- Bagchi S, Wang J, Teixeira-Pinto A, et al. Outcomes Following Kidney Failure From IgA Nephropathy Compared to Diabetic Kidney Disease and Other Glomerular Diseases. Am J Kidney Dis. 2026. PMID: 42913994. doi:10.1053/j.ajkd.2026.06.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。